Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 28;10(4):770-777.
doi: 10.14218/JCTH.2021.00303. Epub 2021 Oct 12.

Impact of Living Donor Liver Transplantation on COVID-19 Clinical Outcomes from a Quaternary Care Centre in Delhi

Imtiakum Jamir  1 , Niteen Kumar  1 , Gaurav Sood  1 , Ashish George  1 , Pankaj Lohia  2 , Samba Siva Rao Pasupuleti  3 , Amrish Sahney  4 , Manav Wadhawan  4 , Ajay Kumar  4 , Abhideep Chaudhary  1
Affiliations

Impact of Living Donor Liver Transplantation on COVID-19 Clinical Outcomes from a Quaternary Care Centre in Delhi

Imtiakum Jamir et al. J Clin Transl Hepatol. .

Abstract

Background and aims: The anticipated fear of serious outcomes in coronavirus infected liver transplant recipients led to disruption of transplant services globally. The aim of our study was to analyze COVID-19 severity in transplant recipients and to compare the difference of COVID-19 clinical outcomes in early (<1 year) vs. late (>1 year) post-transplant period.

Methods: 41 post-living donor liver transplant recipients with COVID-19 infection were studied retrospectively from 1st April 2020 to 28th February 2021.

Results: The median age was 49.00 years with a male preponderance (80.49%). Fifteen patients had infection within 1 year of transplant and 26 were infected after 1 year of transplant. The overall median interval between transplantation and COVID-19 diagnosis was 816.00 days. Fever and malaise were the common presenting symptoms. The most common associated comorbidities were diabetes mellitus (65.85%) and hypertension (46.34%). The severity of illness was mild in 28 (68.29%), moderate in 4 (9.76%), severe in 6 (14.63%) and critical in 3 (7.32%). To identify associated risk factors, we divided our patients into less severe and more severe groups. Except for lymphopenia, there was no worsening of total bilirubin, transaminases, alkaline phosphatase, and gamma-glutamyl transferase in the more severe group. Eight (19.51%) patients required intensive care unit admission and three (7.32%) died, while none suffered graft rejection. In recipients with early vs. late post-transplant COVID-19 infection, there were similar outcomes in terms of severity of COVID-19 illness, intensive care unit care need, requirement of respiratory support, and death.

Conclusion: Living donor liver transplantation can be performed during the COVID-19 pandemic without the fear of poor recipient outcome in cases of unfortunate contraction of severe acute respiratory syndrome coronavirus-2.

Keywords: COVID-19; Living donor liver transplantation, LDLT; Mortality; Perioperative; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interests related to this publication.

Figures

Fig. 1
Fig. 1. Time from liver transplantation to COVID-19 infection.
COVID-19, coronavirus disease-19.
See this image and copyright information in PMC

References

    1. Jha SK, Jamir I, Sisodia K, Kumar N, Sood G, Shanker N, et al. Restarting LDLT During COVID-19: Early Results After Restructuring. Transplant Proc. 2021;53(4):1118–1125. doi: 10.1016/j.transproceed.2020.10.049. - DOI - PMC - PubMed
    1. Lembach H, Hann A, McKay SC, Hartog H, Vasanth S, El-Dalil P, et al. Resuming liver transplantation amid the COVID-19 pandemic. Lancet Gastroenterol Hepatol. 2020;5(8):725–726. doi: 10.1016/S2468-1253(20)30187-4. - DOI - PMC - PubMed
    1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard with Vaccination Data. Available from: https://covid19.who.int/table.
    1. Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. bioRxiv. 2021:2021.04.22.440932. doi: 10.1101/2021.04.22.440932. Published online May 3. - DOI - PMC - PubMed
    1. Clinical Spectrum | COVID-19 Treatment Guidelines. Available from: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/